Where Wegovy, Ozempic, and Mounjaro actually ship.
Region-by-region stock state for the brand-name GLP-1 surface. Sourced from cohort research and operator feedback, with a verifiedAt date on every entry so you can judge freshness. Updated as research lands; check back monthly.
Stable = no recent shortage events. Intermittent = 1-3 week gaps occur. Tight = demand outstrips supply weekly. Rationed = prioritised allocation; off-label patients pushed off. Unavailable = no legal channel currently.
Thailand
Bangkok premium clinics typically have stock; supply gaps appear at 1-2 week intervals at smaller Ekkamai / Sukhumvit clinics. BDMS group (Bumrungrad / Samitivej / Bangkok Hospital) most consistent.
Most reliable injectable GLP-1 in Thailand right now. Novo Nordisk distribution into the SE-Asia clinic network has been steadier than Lilly's.
Available at premium Bangkok clinics (BNH, Bumrungrad, BDMS Wellness).
Wegovy distribution into Thai clinics is much thinner than Ozempic. Most patients route to Ozempic off-label or oral Rybelsus.
United Kingdom
MHRA-approved; private prescription via Boots / Pharmacy2U / independent online clinic. Supply has been stable through 2025-26.
Off-label private prescribing common. More reliable supply than Wegovy.
NHS pathway tightly rationed (BMI ≥35 + comorbidities, Tier 3 specialist referral, 6-12 month waits). Private routes via Boots / Pharmacy2U see 1-3 week stock gaps.
UAE
Cash-pay market, Novo Nordisk and Lilly both maintain steady allocation. DHA / DOH-licensed clinics report no supply gaps in 2026.
MoH-AE registered since 2019. Cash-pay supply steady.
Direct Novo Nordisk allocation deal kept UAE supply steadier than most regions through the 2024-25 shortage.
Singapore
HSA-registered; longevity clinics + hybrid telehealth all stocking. No reported gaps.
More reliable than Wegovy at most SG providers.
Demand outstripped supply post-2024; expect 1-3 week stock gaps at retail apoteks. Hybrid telehealth platforms substitute Ozempic when Wegovy runs dry.
Vietnam
Even FV and Family Medical Practice run dry occasionally. Confirm stock at intake before booking.
Generally more stable than tirzepatide / Mounjaro in Vietnam.
The licensed-for-weight option in Vietnam (semaglutide is T2D-framed only per Bộ Y Tế). Vinmec leads on liraglutide / Saxenda for weight management.
Patchier than Ozempic. International clinics (FV, Family Medical) report 2-4 week gaps.
Bali / Indonesia
BPOM tightened GLP-1 import enforcement late 2025; supply intermittent across all channels. Siloam Denpasar + Kasih Ibu have the deepest BPOM-channel pharma reserves.
BPOM-channel; supply intermittent late 2025 onwards but Siloam + BIMC most reliable.
BPOM-channel only. Slightly steadier than tirzepatide in Bali, but still goes intermittent.
United States
Brand stable post-Feb-Mar 2026 reclass. Compounded path narrowed under FDA personalisation rules but 503A pharmacies and major telehealth (Henry, Mochi, Ro) still ship.
Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.
Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.
Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans.
Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable.
EU
EMA-approved 2022; private prescription routes stable across member states.
Mostly recovered post-2024 shortage. Spain + Portugal + Netherlands stable; Germany + France still see 1-3 week gaps. Cross-border arbitrage via Spain is real and legal under EEA Directive 2011/24.
Norway
Apotek dispense after Norwegian or EEA prescription, no current gaps reported.
Steadier than Wegovy at Norwegian apoteks through the 2024-25 shortage.
Mostly recovered by Q2 2026 across Norwegian apoteks but ask before relying on availability.
Australia
TGA-approved for T2D, off-label weight prescribing legal. Juniper / Eucalyptus / Hub Health all stocking; no reported gaps.
Recovered from the severe 2023-24 shortage that prioritised T2D patients over weight-only access.
August 2024 launch eased the pressure, but Wegovy supply remains tighter than tirzepatide.
New Zealand
Medsafe-approved Feb 2026 launch via Eli Lilly. Early days but supply stable at NZ telehealth operators.
Mexico
Same Lilly product as US, no supply pressure. Tijuana / cross-border clinics stock consistently.
Canada
Health Canada-approved. Felix / Maple / Tia Health all stocking; major pharmacy chains carry.
Supply state changes faster than this page does. Always confirm stock at the specific provider before booking. Match through Panya and the live vendor we route you to is a current operator we have touched in the last 30 days.